VolitionRx Limited (VNRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on March 31, 2026. VolitionRx Limited, a Delaware corporation listed on NYSE American, held a special meeting of stockholders in London to vote on two critical corporate governance proposals.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate actions and voting results rather than financial performance.
Material Changes and Voting Results
On the record date of February 9, 2026, the Company had 135,565,326 shares of common stock outstanding. At the Special Meeting, 80,508,751 shares were present or represented by proxy. Stockholders approved two proposals:
- Proposal 1 (Share Issuance): Approved the issuance of additional shares exceeding 20% of outstanding shares to Lind Global Asset Management XII LLC to comply with NYSE American Rule 713.
- Votes For: 44,152,648
- Votes Against: 14,095,382
- Votes Abstained: 1,114,276
- Broker Non-Votes: 21,146,445
- Proposal 2 (Reverse Stock Split): Approved an amendment to the Certificate of Incorporation authorizing a reverse stock split at a ratio between 1-for-5 and 1-for-20, to be determined by the Board of Directors.
- Votes For: 62,838,654
- Votes Against: 16,451,299
- Votes Abstained: 1,218,798
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors beyond the context of the voting proposals. The approval of the share issuance indicates a strategic move to maintain listing compliance, while the reverse split authorization suggests potential future actions to adjust share price or structure.
Investor Verification Checklist
- Verify the definitive proxy statement (Schedule 14A) filed on February 11, 2026, for detailed rationale behind the Lind Global Asset Management transaction.
- Monitor future Board announcements regarding the specific ratio and timing of the authorized reverse stock split.
- Confirm the impact of the new share issuance on total outstanding share count and potential dilution.
- Review subsequent filings for the execution of the reverse stock split and any related capital structure changes.